Abstract
Background/Aim: Sphingomyelin phosphodiesterase acid-like 3B (SMPDL3B) is an enzyme involved in lipid metabolism and cellular signaling. SMPDL3B expression is up-regulated in several cancers, suggesting its potential as a novel prognostic biomarker and therapeutic target for cancer treatment. However, its role in lung cancer remains unclear. In this study, we evaluated the biological role of SMPDL3B in lung cancer.
Materials and Methods: SMPDL3B expression in lung adenocarcinoma (LUAD) tissues and cells was validated using quantitative real-time PCR and western blotting. To determine the role of SMPDL3B in LUAD cells, a small interfering RNA targeting SMPDL3B was used to suppress intracellular gene expression. Cell proliferation was performed using MTT and colony formation assays, and transwell assays with or without Matrigel were used to evaluate the role of SMPDL3B in LUAD cells migration and invasion.
Results: SMPDL3B was overexpressed in LUAD tissues and cells. Knockdown of SMPLD3B significantly inhibited cell proliferation by regulating cell cycle progression and also prevented the migration and invasion of LUAD cells.
Conclusion: SMPDL3B plays a role in LUAD, suggesting its potential as a therapeutic target for selective and personalized lung cancer treatment.
- Received April 3, 2025.
- Revision received May 14, 2025.
- Accepted May 26, 2025.
- Copyright © 2025 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.






